Key terms

About HOLX

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment focuses on products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment offers the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest HOLX news

Apr 08 9:45pm ET RBC Capital Sticks to Its Hold Rating for Hologic (HOLX) Apr 03 9:54am ET UPS upgraded, PepsiCo downgraded: Wall Street’s top analyst calls Apr 03 5:59am ET Citi upgrades Hologic to Buy on conservative annual outlook Apr 03 5:39am ET Hologic upgraded to Buy from Neutral at Citi Feb 07 6:00am ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Elanco Animal Health (ELAN), Hologic (HOLX) and Centene (CNC) Feb 05 8:45pm ET RBC Capital Reaffirms Their Hold Rating on Hologic (HOLX) Feb 05 4:20am ET Analysts Offer Insights on Healthcare Companies: Cigna (CI), Evolus (EOLS) and Hologic (HOLX) Feb 05 4:17am ET Hologic: Strong Q1 Performance and Promising Growth Trajectory Justify Buy Rating Feb 04 4:07pm ET Hologic price target raised to $84 from $82 at Morgan Stanley Feb 04 3:20pm ET Analysts Offer Insights on Healthcare Companies: Cigna (CI) and Hologic (HOLX) Feb 02 8:03am ET Hologic price target raised to $90 from $83 at Needham Feb 02 7:25am ET Hologic’s Hold Rating: Balancing Exceeded Expectations with Modest Growth and Market Position Feb 02 6:52am ET Hologic price target raised to $79 from $78 at UBS Feb 02 6:00am ET Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL) and Hologic (HOLX) Feb 02 5:36am ET Hologic: Hold Rating Justified by Solid Performance and Fair Valuation Feb 01 5:38pm ET Hologic’s Genius Digital Diagnostics System cleared by FDA Feb 01 4:04pm ET Hologic raises FY24 EPS view to $3.97-$4.12 from $3.90-$4.10, consensus $4.00 Feb 01 4:03pm ET Hologic sees Q2 EPS 95c-$1.00, consensus 98c Feb 01 4:02pm ET Hologic reports Q1 non-GAAP EPS 98c, consensus 95c Feb 01 4:02pm ET Hologic reports Q1 EPS $1.03, consensus 95c Feb 01 1:18pm ET Notable companies reporting after market close Jan 26 8:46pm ET RBC Capital Keeps Their Hold Rating on Hologic (HOLX) Jan 23 7:47am ET Hologic revenue to rise in from higher non-COVID diagnostic volume, says Argus

No recent press releases are available for HOLX

HOLX Financials

1-year income & revenue

Key terms

HOLX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

HOLX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms